Ultime notizie per Immunic (NASDAQ:IMUX) Azioni

Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic Inc

WIIM

Evolent Health shares are trading lower after Stephens & Co. downgraded the stock from Overweight to Equal-Weight and announced a price target of $16.

Benchmark analyst Mike Hickey maintains Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and raises the price target from $14 to $16.

News

Price Target

Analyst Ratings

SRAD

Benchmark Maintains Buy on Sportradar Gr, Raises Price Target to $16

Truist Securities analyst Keith Hughes maintains CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) with a Buy and raises the price target from $110 to $120.

Truist Securities Maintains Buy on CRH, Raises Price Target to $120

Scotiabank analyst Andres Coello maintains Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILAK#NASDAQ">LILAK</a>) with a Sector Outperform and lowers the price target from $9.4 to $8.3.

LILAK

Scotiabank Maintains Sector Outperform on Liberty Latin America, Lowers Price Target to $8.3

Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) said that its investment strategy in the United States remains unaffected despite Donald Trump&#8217;s recent election win.
The statement came after speculation about potential changes to its plans following Trump&#8217;s critical remarks on Taiwan&#8217;s semiconductor industry, SCMP <a target="_blank" href="https://www.scmp.com/tech/policy/article/3285673/taiwans-chipmaker-tsmc-says-us-investment-plan-unchanged-after-trumps-election?module=perpetual_scroll_0&amp;pgtype=article" rel="noreferrer noopener">reports</a>.
Taiwan Semiconductor, a major supplier to tech giants like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), is proceeding with its $65 billion investment in advanced semiconductor production facilities in Arizona.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820580/applovins-high-valuation-and-expansion-beyond-gaming-prompt-analyst-caution" rel="noreferrer noopener">AppLovin&#8217;s High Valuation and Expansion Beyond Gaming Prompt Analyst Caution</a>
Throughout his campaign, Trump accused Taiwan <a target="_blank" href="https://www.benzinga.com/news/24/11/41780976/chip-stocks-like-nvidia-broadcom-taiwan-semi-gain-after-trump-win-whats-going-on" rel="noreferrer noopener">of undermining the</a> U.S. chip industry.
In a podcast appearance last month, he criticized the Chips Act, labeling it &#8220;a poor strategy,&#8221; suggesting tariffs would have been a more practical approach than offering subsidies to wealthy corporations.
The Biden administration recently notified Congress about imminent <a target="_blank" href="https://www.benzinga.com/government/24/11/41811866/taiwan-semi-and-globalfoundries-finalize-major-us-funding-deals-eye-growth-in-chip-manufacturing" rel="noreferrer noopener">awards from the</a> Chips Act, expected to benefit Taiwan Semiconductor, GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>), and a third unnamed semiconductor company.
The Act incentivizes chipmakers to expand U.S. production, allocating $37 billion across 21 preliminary agreements.
Despite concerns over Trump&#8217;s criticism of the Chips Act, Taiwan Semiconductor&#8217;s stock has shown resilience. The stock gained further momentum following a surge in Nvidia&#8217;s share price.
Taiwan Semiconductor has notified its clients in mainland China that it will cease production of advanced chips for them. The decision affects customers seeking chip designs using 7-nanometer technology or smaller, SCMP <a target="_blank" href="https://www.scmp.com/tech/tech-war/article/3285805/tsmc-halts-advanced-chip-orders-mainland-china-after-us-export-curbs-evasion-source" rel="noreferrer noopener">cites</a> familiar sources. The notice reportedly takes effect next week.
Mainland China contributed 11% to Taiwan Semiconductor&#8217;s third-quarter revenue, whereas North America accounted for 71%, SCMP cites Visible Alpha by S&amp;P Global Market Intelligence data.
Taiwan Semiconductor posted <a target="_blank" href="https://www.benzinga.com//node/41373163" rel="noreferrer noopener">fiscal third-quarter revenue</a> of 759.69 billion New Taiwan dollars ($23.50 billion), marking a 39% increase and surpassing both its guidance range of $22.4 billion—$23.2 billion and analyst expectations.
The company credited strong demand for smartphones and AI applications, driven by its advanced 3nm and 5nm technologies, with Needham&#8217;s Charles Shi noting <a target="_blank" href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" rel="noreferrer noopener">Apple as a key contributor</a>. Gross margin widened by 350 basis points to 57.8%. For the fourth quarter, Taiwan Semiconductor projects revenue of $26.1 billion—$26.9 billion, exceeding the Street&#8217;s forecast of $24.86 billion.
Taiwan Semiconductor stock gained over 98% year-to-date.
Price Actions: TSM stock is up 2.60% at $206.43 premarket at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces" target="_blank" rel="noreferrer noopener">Roblox Tightens Safety, Bans Preteens from Virtual Social Spaces</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Movers

Tech

Media

AAPL

NVDA

Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report

Truist Securities analyst Michael Swartz maintains Acushnet Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) with a Hold and raises the price target from $65 to $68.

GOLF

Truist Securities Maintains Hold on Acushnet Hldgs, Raises Price Target to $68

SKYE

Skye Bioscience shares are trading higher after the company reported better-than-expected Q3 EPS results.

Benchmark analyst Daniel Kurnos maintains Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) with a Buy and raises the price target from $21 to $23.

TGNA

Benchmark Maintains Buy on Tegna, Raises Price Target to $23

PSTX

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Scotiabank analyst Mario Saric maintains Killam Apartment REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KMP#TSX">KMP</a>) with a Sector Perform and raises the price target from C$20.5 to C$21.

TSX:KMP

TSX:KMP/UN

Scotiabank Maintains Sector Perform on Killam Apartment REIT, Raises Price Target to C$21

Truist Securities analyst Neal Dingmann maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Buy and lowers the price target from $36 to $33.

Truist Securities Maintains Buy on APA, Lowers Price Target to $33

Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) co-founder Sergey Nazarov on Friday said &#8220;the party&#8217;s back on&#8221; for cryptocurrency markets, predicting substantial industry growth amid potential changes in the U.S. regulatory <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">landscape under Donald Trump&#8216;s presidency</a>.
What Happened: &#8220;This is just the beginning basically. This is like the party&#8217;s back on and there&#8217;s going to be huge huge growth in all categories of crypto,&#8221; Nazarov <a href="https://x.com/ChainLinkGod/status/1854553832396828796">told</a> CNBC, expressing optimism about the industry&#8217;s trajectory.
Nazarov emphasized that cryptocurrency&#8217;s fundamental benefits to society outweigh regulatory concerns. 
&#8220;I think that crypto fundamentally benefits society and makes things work in a much more reliable way than they do now,&#8221; he stated, citing <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41654131/pro-crypto-congress-in-2025-experts-see-stablecoins-as-key-area-for-advancement">stablecoins</a> and tokenized funds as examples of successful implementation.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a>
Drawing parallels with Asian crypto hubs, Nazarov pointed to successful regulatory frameworks in <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40901724/singapores-dbs-bank-launches-bitcoin-and-ethereum-options-trading-for-institutional-client">Singapore</a> and Hong Kong.
&#8220;More regulation doesn&#8217;t mean better markets, it just means kind of muted markets with less innovation,&#8221; he explained, advocating for a more permissive approach to <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">cryptocurrency regulation</a>.
Price Action: Chainlink has followed other cryptocurrencies&#8217; uptrend since the start of October.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Price</td>
<td>1-day performance</td>
<td>7-day performance</td>
<td>30-day performance</td>
</tr>
<tr>
<td>$13.32</td>
<td>+8.6%</td>
<td>+14.7%</td>
<td>+25.6%</td>
</tr>
</tbody>
</table>
</figure>
The Chainlink co-founder&#8217;s perspectives align with growing institutional interest in digital assets, a topic that will be further explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814454/donald-trump-could-pardon-ross-ulbricht-january-6-protestors-and-one-other-controversial-f">Donald Trump Could Pardon Ross Ulbricht, January 6 Protestors And One Other Controversial Figure, Polymarket Traders Speculate</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$LINK

'The Party's Back On'—Chainlink Co-Founder Predicts Major Crypto Growth Under Trump Presidency

EXFY

Expensify shares are trading higher after the company reported better-than-expected Q3 financial results.

Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported a third-quarter 2024 adjusted EPS of 80 cents, beating the management guidance of 77 cents to 79 cents and the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">Wall Street estimate of 78 cents</a>.
This was driven by top-line strength in Medical Products &amp; Therapies and Kidney Care, continued improvements in the integrated supply chain, and disciplined operating expense management.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41403928/us-hospitals-face-critical-iv-fluid-shortage-after-baxter-facility-shuts-down-due-to-hurricane-hel" rel="noreferrer noopener">US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene</a>
The Deerfield, Illinois-based company reported sales of $3.85 billion, in line with consensus.
Baxter&#8217;s worldwide sales include continuing sales of $2.69 billion and discontinued operations (kidney care) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41840934/baxter-reports-third-quarter-2024-results" rel="noreferrer noopener">sales of $1.15 billion</a>.
Excluding Q3 2023 BioPharma Solutions (BPS) sales and including sales of Kidney Care in both periods, worldwide Baxter sales grew 4% on both a reported and constant currency basis, in line with the company&#8217;s prior guidance.
Adjusted EPS from continuing operations was 49 cents, up 14% year-over-year.
Revenue from Medical Products &amp; Therapies increased 7% to $1.34 billion, Healthcare Systems &amp; Technologies sales increased 1% to $752 million, and Pharmaceuticals sales were up 1% to $588 million.
Last week, Baxter said it has restarted North Cove&#8217;s highest-throughput IV solutions manufacturing line.
At its peak operation (before Hurricane Helene), this line represented approximately 25% of the site&#8217;s total production and approximately 50% of the site&#8217;s production of one-liter IV solutions, the most commonly used size by hospitals and clinics.
Baxter&#8217;s current expectation is that new product from North Cove could begin shipping to distributors and customers by the end of November, ahead of its original expectations.
Guidance: &#8220;While the hurricane&#8217;s aftermath is expected to have an impact on our near-term financial outlook, we remain confident in Baxter&#8217;s outlook and growth trajectory following completion of the pending Kidney Care sale,&#8221; said José (Joe) Almeida, chair, president &amp; CEO.
Baxter expects fourth-quarter adjusted EPS of 77 cents to 81 cents, with 50 cents to 53 cents expected from continuing operations.
For the fourth quarter, the company forecasts sales from continuing operations to decline in low-single digits on a reported and constant currency basis.
For fiscal year 2024, Baxter sees adjusted EPS of $2.90-$2.94 compared to a consensus of $2.95 and <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40191263/baxter-lifts-annual-outlook-after-strong-q2-beat-medical-devices-sales" rel="noreferrer noopener">prior guidance of $2.93-$3.01</a>, including $1.81-$1.84 from continuing operations.
The company <a target="_blank" href="https://s22.q4cdn.com/911189824/files/doc_financials/2024/q3/Baxter_Reports_Third-Quarter_2024_Results_Presentation.pdf" rel="noreferrer noopener">expects</a> sales (from continuing operations) growth of around 2%.
Baxter anticipates a full-year 2025 adjusted operating margin of approximately 16.5% on a continuing operations basis, which reflects an anticipated 100 basis point negative impact due to stranded costs. The company expects to offset these stranded costs in 2027.
Price Action: BAX stock is down 1.22% at $35.60 during the premarket session at last check Friday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41843534/astrazeneca-amgens-asthma-drug-aces-late-stage-study-in-patients-with-chronic-rhinosinusitis" target="_blank" rel="noreferrer noopener">AstraZeneca/Amgen&#8217;s Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Health Care

General

Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook

Truist Securities analyst Tobey Sommer maintains AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) with a Buy and lowers the price target from $50 to $47.

Truist Securities Maintains Buy on AMN Healthcare Services, Lowers Price Target to $47

Benchmark analyst Mike Hickey reiterates PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) with a Hold.

Reiteration

PENN

Benchmark Reiterates Hold on PENN Entertainment

LTRX

Lantronix shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates. Also, the company announced the acquisition of DXS's NetComm enterprise IoT portfolio.

Scotiabank analyst Nick Altmann maintains JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Sector Perform and raises the price target from $25 to $30.

FROG

Scotiabank Maintains Sector Perform on JFrog, Raises Price Target to $30

UEIC

Universal Electronics shares are trading higher after the company issued Q4 revenue guidance above estimates. Also, Rosenblatt upgraded the stock from Neutral to Buy.

Piper Sandler analyst Brent Bracelin maintains OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Overweight and raises the price target from $34 to $37.

Piper Sandler Maintains Overweight on OneStream, Raises Price Target to $37

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bluebird Bio (BLUE – Research Report), Immunic (IMUX...

Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)

Immunic ($IMUX), a clinical-stage biotechnology company, is developing a small-molecule oral medicine for the treatment of Multiple Sclerosis (MS)....

B. Riley Reacts to Immunic's Update on Clinical Benefits of Vidofludimus Calcium

Clinical-stage biotechnology company Immunic Therapeutics' ($IMUX) stock continues to gain consistent Buy ratings from analysts. On TipRanks, IMUX ...

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts

Immunic (IMUX) announced the outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear...

Immunic announces outcome of ENSURE program

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at $5.00. Fa...

Promising Phase 3 Trial Results and Strategic Insights Drive Buy Rating for Vidofludimus Calcium

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Immunic Q3 2024 Earnings Preview

Immunic GAAP EPS of -$0.24 misses by $0.02

"During the third quarter, we have continued to advance both our phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and o...

Comments

Immunic

Notizie

Ultime notizie per Immunic (NASDAQ:IMUX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO